IL284837A - Pharmaceutical combination comprising tno155 and a pd-1 inhibitor - Google Patents
Pharmaceutical combination comprising tno155 and a pd-1 inhibitorInfo
- Publication number
- IL284837A IL284837A IL284837A IL28483721A IL284837A IL 284837 A IL284837 A IL 284837A IL 284837 A IL284837 A IL 284837A IL 28483721 A IL28483721 A IL 28483721A IL 284837 A IL284837 A IL 284837A
- Authority
- IL
- Israel
- Prior art keywords
- tno155
- inhibitor
- pharmaceutical combination
- combination containing
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804707P | 2019-02-12 | 2019-02-12 | |
| PCT/IB2020/051030 WO2020165733A1 (en) | 2019-02-12 | 2020-02-10 | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284837A true IL284837A (en) | 2021-08-31 |
Family
ID=69724012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284837A IL284837A (en) | 2019-02-12 | 2021-07-13 | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220160706A1 (enExample) |
| EP (1) | EP3923940B1 (enExample) |
| JP (1) | JP2022519385A (enExample) |
| KR (1) | KR20210126652A (enExample) |
| CN (1) | CN113395967A (enExample) |
| AU (1) | AU2020222295B2 (enExample) |
| BR (1) | BR112021015487A2 (enExample) |
| CA (1) | CA3129031A1 (enExample) |
| CL (1) | CL2021002100A1 (enExample) |
| IL (1) | IL284837A (enExample) |
| MX (1) | MX2021009562A (enExample) |
| TW (1) | TW202045172A (enExample) |
| WO (1) | WO2020165733A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12138262B2 (en) | 2018-09-29 | 2024-11-12 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition |
| CN120208856A (zh) | 2018-09-29 | 2025-06-27 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN113382731A (zh) * | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | 包含tno155和瑞博西尼的药物组合 |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| KR20230038197A (ko) | 2020-07-08 | 2023-03-17 | 노파르티스 아게 | Shp2의 활성 억제를 위한 화합물 및 조성물의 제조 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| CN116710094A (zh) * | 2020-12-22 | 2023-09-05 | 诺华股份有限公司 | 包含kras g12c抑制剂的药物组合以及kras g12c抑制剂用于治疗癌症的用途 |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US12390469B2 (en) | 2021-05-05 | 2025-08-19 | Huyabio International, Llc | SHP2 inhibitor monotherapy and uses thereof |
| CA3217084A1 (en) | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| KR20250169290A (ko) | 2023-04-14 | 2025-12-02 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN108136003A (zh) * | 2015-07-29 | 2018-06-08 | 诺华股份有限公司 | 抗pd-1和抗m-csf抗体在癌症治疗中的联合应用 |
| JP7503380B2 (ja) * | 2017-01-10 | 2024-06-20 | ノバルティス アーゲー | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
| CN113382731A (zh) * | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | 包含tno155和瑞博西尼的药物组合 |
| EP4249000A3 (en) * | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
-
2020
- 2020-02-10 US US17/430,203 patent/US20220160706A1/en active Pending
- 2020-02-10 JP JP2021546382A patent/JP2022519385A/ja active Pending
- 2020-02-10 MX MX2021009562A patent/MX2021009562A/es unknown
- 2020-02-10 BR BR112021015487-6A patent/BR112021015487A2/pt not_active IP Right Cessation
- 2020-02-10 WO PCT/IB2020/051030 patent/WO2020165733A1/en not_active Ceased
- 2020-02-10 EP EP20707826.2A patent/EP3923940B1/en active Active
- 2020-02-10 CN CN202080012523.1A patent/CN113395967A/zh active Pending
- 2020-02-10 TW TW109104043A patent/TW202045172A/zh unknown
- 2020-02-10 CA CA3129031A patent/CA3129031A1/en active Pending
- 2020-02-10 KR KR1020217028653A patent/KR20210126652A/ko not_active Ceased
- 2020-02-10 AU AU2020222295A patent/AU2020222295B2/en active Active
-
2021
- 2021-07-13 IL IL284837A patent/IL284837A/en unknown
- 2021-08-10 CL CL2021002100A patent/CL2021002100A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020222295A1 (en) | 2021-08-05 |
| AU2020222295B2 (en) | 2023-04-06 |
| EP3923940B1 (en) | 2025-12-03 |
| EP3923940A1 (en) | 2021-12-22 |
| US20220160706A1 (en) | 2022-05-26 |
| CL2021002100A1 (es) | 2022-04-18 |
| KR20210126652A (ko) | 2021-10-20 |
| CN113395967A (zh) | 2021-09-14 |
| TW202045172A (zh) | 2020-12-16 |
| BR112021015487A2 (pt) | 2021-10-05 |
| CA3129031A1 (en) | 2020-08-20 |
| JP2022519385A (ja) | 2022-03-23 |
| MX2021009562A (es) | 2021-09-08 |
| WO2020165733A1 (en) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284837A (en) | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor | |
| IL284835A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| IL292643A (en) | Ras inhibitors | |
| IL292644A (en) | Ras inhibitors | |
| IL292642A (en) | Ras inhibitors | |
| EP4007752C0 (en) | Kif18a inhibitors | |
| IL269466A (en) | Pd-1/pd-l1 inhibitors | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| IL285178A (en) | Compounds and uses thereof | |
| EP4007753C0 (en) | Kif18a inhibitors | |
| DK3999506T3 (da) | Parp1-hæmmere | |
| IL289612A (en) | Hpk1 inhibitors and uses thereof | |
| IL267617A (en) | A pharmaceutical combination containing an alk inhibitor and a shp2 inhibitor | |
| IL284508A (en) | Irreversible inhibitors of menin-mll interaction | |
| EP3904351A4 (en) | FAK INHIBITOR AND COMBINATION OF ACTIVE SUBSTANCES THEREOF | |
| EP3746071A4 (en) | GCN2 INHIBITORS AND THEIR USES | |
| EP3746075A4 (en) | GCN2 INHIBITORS AND THEIR USES | |
| IL283330A (en) | Combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| IL291191A (en) | Cdk inhibitors and their use as pharmaceuticals | |
| DK3595667T3 (da) | Farmaceutiske sammensætninger omfattende en jak-hæmmer | |
| EP3980011A4 (en) | INHIBITORS OF SARM1 | |
| EP4038060C0 (en) | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR | |
| IL284514A (en) | Halo-allylamine compounds and use thereof | |
| EP4003986A4 (en) | Inhibitor compounds | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS |